A
Alcista
Alcista · 25%SXTC
$2.24
Precio del escenario
$0.065
-0.004 (-5.52%)Al cierre
Loading chart…
- Máximo
- 0.082
- Apertura
- 0.082
- Precio medio ponderado por volumen
- 0.07
- Volumen
- 263.85M
- Capitalización
- 1.01M
- Mínimo
- 0.062
- Importe
- 18.37M
- EV/EBITDA, TTM
- 0.00
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
Análisis de IA of China SXT Pharmaceuticals Inc (SXTC)
VenderChina SXT Pharmaceuticals Inc (SXTC) is not a good buy right now due to its drastic price decline of 93.83% over the last five days and a current RSI of 28.539, indicating oversold conditions but also significant bearish momentum. The company has faced severe financial difficulties, highlighted by a forward P/E of 0 and a price-to-sales ratio of 0.398846, which suggest that the stock is undervalued but also raises concerns about its viability. The main risk is the 100% year-to-date decline, reflecting a complete loss of investor confidence and the potential for further downside.
Métricas de valoración
El PER previsto actual de China SXT Pharmaceuticals Inc (SXTC) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para SXTC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.510-09NewsfilterChina SXT Pharmaceuticals Closes $12 Million Direct Offering
8.510-08PRnewswireChina SXT Pharmaceuticals Announces Direct Offering of 8 Million Shares
- 8.507-24Newsfilter
China SXT Pharmaceuticals Closes $9 Million Direct Offering
8.507-23seekingalphaChina SXT Pharmaceuticals Secures $9M Direct Offering
9.502-02BenzingaDarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
Preguntas frecuentes sobre SXTC, respondidas por Alphio AI
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
China SXT Pharmaceuticals Inc (SXTC) is not a good buy right now due to its drastic price decline of 93.83% over the last five days and a current RSI of 28.539, indicating oversold conditions but also significant bearish momentum. The company has faced severe financial difficulties, highlighted by a forward P/E of 0 and a price-to-sales ratio of 0.398846, which suggest that the stock is undervalued but also raises concerns about its viability. The main risk is the 100% year-to-date decline, reflecting a complete loss of investor confidence and the potential for further downside.
Comunidad
Más ↗
$GNPX October 2024 and October 2025. Two Octobers in a row produced strong rallies, and anyone who has followed GNPX closely would recognize that. In 2024 the month finished up about 522%...... The sample is two years, both moves were tied to a thin float, and the current float is even smaller than it was over the last two years, so it may be worth watching for a trade. For that reason, I mentioned GNPX as a potential $SXTC type mover. Let's see what this month brings.
Mostrar más
The only micro float bio name similar to $SXTC, which rose over 500% today, is $GNPX, with just a 480K free float and also a cash-rich company with a net cash per share of $15 per DT.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.